Collateral sensitivity networks reveal evolutionary instability and novel treatment strategies in ALK mutated non-small cell lung cancer
Abstract Drug resistance remains an elusive problem in cancer therapy, particularly for novel targeted therapies. Much work is focused upon the development of an arsenal of targeted therapies, towards oncogenic driver genes such as ALK-EML4, to overcome the inevitable resistance that develops over t...
Guardado en:
Autores principales: | Andrew Dhawan, Daniel Nichol, Fumi Kinose, Mohamed E. Abazeed, Andriy Marusyk, Eric B. Haura, Jacob G. Scott |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/6b5c83346aaa41bdb7166d600b70caef |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Exploiting evolutionary steering to induce collateral drug sensitivity in cancer
por: Ahmet Acar, et al.
Publicado: (2020) -
Antibiotic collateral sensitivity is contingent on the repeatability of evolution
por: Daniel Nichol, et al.
Publicado: (2019) -
Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer
por: Barrows SM, et al.
Publicado: (2019) -
Value of CT features for predicting EGFR mutations and ALK positivity in patients with lung adenocarcinoma
por: Xiaoyu Han, et al.
Publicado: (2021) -
Resistance to targeted therapies as a multifactorial, gradual adaptation to inhibitor specific selective pressures
por: Robert Vander Velde, et al.
Publicado: (2020)